Literature DB >> 10720689

Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha.

R Minami1, K Muta, C Ilseung, Y Abe, J Nishimura, H Nawata.   

Abstract

OBJECTIVE: Interleukin-6 (IL-6) is a multifunctional cytokine affecting growth and survival of normal B cell lineage and multiple myeloma cells. To test the hypothesis that IL-6, as well as other hematopoietic growth factors, may enhance apoptosis of target cells, we investigated the effect of IL-6 on myeloma cells in the presence of IFN-alpha, which is prescribed for patients with multiple myeloma.
MATERIALS AND METHODS: Four myeloma cell lines, PCM6, NOP-2, U266, RPMI8226 were tested. We determined the induction of apoptosis by flow cytometry, using an FITC-Annexin V.
RESULTS: IFN-alpha induced apoptosis on myeloma cell lines, and this apoptosis was further enhanced in the presence of IL-6, via activation of caspase 3. During induction of this apoptosis, the expression of c-Myc and Fas increased. The addition of IL-6 further increased the expression of Fas, but not that of c-Myc. Bcl-2, Bcl-x, and p53 were not affected by the addition of IL-6 and/or IFN-alpha. Addition of a PI-3-K inhibitor interfered with the enhancing effect of IL-6 on the apoptosis induced by IFN-alpha.
CONCLUSION: We propose that IL-6 has the death signal, as well as growth promoting effects, and that PI-3-K may play a key role in the induction of apoptosis by IL-6.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720689     DOI: 10.1016/s0301-472x(99)00156-3

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Involvement of interferon-alpha in the regulation of apoptosis of cells of the hypothalamo-hypophyseal-adrenocortical system of aged mice in oxidative stress.

Authors:  E D Bazhanova; D L Teplyi
Journal:  Neurosci Behav Physiol       Date:  2005-05

Review 2.  Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.

Authors:  Quan Chen; Subrata Ray; Mohamad A Hussein; Gordan Srkalovic; Alexandru Almasan
Journal:  Leuk Lymphoma       Date:  2003-07

3.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

4.  DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.

Authors:  Kazuya Ishiguro; Hiroshi Kitajima; Takeshi Niinuma; Tadao Ishida; Reo Maruyama; Hiroshi Ikeda; Toshiaki Hayashi; Hajime Sasaki; Hideki Wakasugi; Koyo Nishiyama; Tetsuya Shindo; Eiichiro Yamamoto; Masahiro Kai; Yasushi Sasaki; Takashi Tokino; Hiroshi Nakase; Hiromu Suzuki
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 9.941

5.  Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis.

Authors:  Kazuya Ishiguro; Hiroshi Kitajima; Takeshi Niinuma; Reo Maruyama; Naotaka Nishiyama; Hitoshi Ohtani; Gota Sudo; Mutsumi Toyota; Hajime Sasaki; Eiichiro Yamamoto; Masahiro Kai; Hiroshi Nakase; Hiromu Suzuki
Journal:  Cell Death Discov       Date:  2021-01-12

Review 6.  Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.

Authors:  Li Zhang; Yu-Tzu Tai; Matthew Zhi Guang Ho; Lugui Qiu; Kenneth C Anderson
Journal:  Exp Hematol Oncol       Date:  2017-07-14

7.  Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis.

Authors:  Daniela N Petrusca; Denise Toscani; Feng-Ming Wang; Cheolkyu Park; Colin D Crean; Judith L Anderson; Silvia Marino; Khalid S Mohammad; Dan Zhou; Rebecca Silbermann; Quanhong Sun; Noriyoshi Kurihara; Deborah L Galson; Nicola Giuliani; G David Roodman
Journal:  J Hematol Oncol       Date:  2018-10-04       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.